GRAIL (NASDAQ:GRAL) Reaches New 52-Week High – Time to Buy?

GRAIL, Inc. (NASDAQ:GRAL) shares hit a new 52-week high during trading on Monday . The stock traded as high as $103.33 and last traded at $102.5880, with a volume of 955613 shares trading hands. The stock had previously closed at $93.55.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Wednesday, October 8th. Guggenheim raised GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Wednesday, November 12th. UBS Group set a $75.00 price target on shares of GRAIL in a research report on Friday, October 3rd. Finally, Canaccord Genuity Group boosted their price target on shares of GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $75.00.

GRAIL Trading Up 2.3%

The stock has a market capitalization of $4.29 billion, a PE ratio of -9.47 and a beta of 4.31. The firm has a 50-day moving average price of $74.61 and a 200-day moving average price of $51.28.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.46) EPS for the quarter, topping the consensus estimate of ($3.40) by $0.94. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. The business had revenue of $36.19 million for the quarter, compared to analyst estimates of $33.83 million. Sell-side analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, President Joshua J. Ofman sold 6,114 shares of GRAIL stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $82.01, for a total value of $501,409.14. Following the completion of the sale, the president owned 381,818 shares of the company’s stock, valued at approximately $31,312,894.18. This trade represents a 1.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 7,239 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $68.88, for a total value of $498,622.32. Following the completion of the sale, the chief executive officer owned 727,388 shares in the company, valued at $50,102,485.44. This represents a 0.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 113,295 shares of company stock valued at $7,380,888 over the last three months.

Institutional Trading of GRAIL

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in GRAIL by 3.4% during the 1st quarter. Vanguard Group Inc. now owns 1,499,740 shares of the company’s stock valued at $38,303,000 after acquiring an additional 48,645 shares during the period. Farallon Capital Management LLC raised its stake in shares of GRAIL by 168.7% during the 3rd quarter. Farallon Capital Management LLC now owns 1,349,000 shares of the company’s stock valued at $79,766,000 after purchasing an additional 847,000 shares during the period. AQR Capital Management LLC lifted its holdings in GRAIL by 61.0% during the 1st quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company’s stock worth $33,991,000 after purchasing an additional 506,440 shares in the last quarter. Geode Capital Management LLC boosted its stake in GRAIL by 60.4% in the 2nd quarter. Geode Capital Management LLC now owns 757,770 shares of the company’s stock worth $38,969,000 after purchasing an additional 285,331 shares during the period. Finally, Wealthquest Corp purchased a new stake in shares of GRAIL in the first quarter worth about $18,247,000.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.